REG - BSF Enterprise PLC - US Investor Roadshow & Appointment of US IR Agency

BSF EnterpriseAnnouncement

08/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230608:nRSH0195Ca&default-theme=true

RNS Number : 0195C  BSF Enterprise PLC  08 June 2023

8 June 2023

 

BSF Enterprise PLC

("BSF" or the "Company")

 

US Investor Roadshow

and

Appointment of US Investor Relations Agency

 

BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and
owner of pioneering UK-based clinical and cellular agriculture company 3D
Bio-Tissues, is pleased to announce that it will be undertaking a US investor
roadshow between June 26-30, 2023 and has appointed a US Investor Relations
agency to manage its communications in the region. This follows on from the
Company's successful listing on the OTCQB market, announced on 25 May 2023.

 

Trading on the OTCQB market provides BSF with access to one of the world's
largest investment markets.  BSF is therefore seeking to maximise the
potential of its OTCQB listing through a programme of regular, pro-active
engagement with the US investment community.

 

The first step in this programme will be a US investor roadshow. The roadshow
is being facilitated by Skyline Corporate Communications Group, LLC
("Skyline") and BSF will retain the services of Skyline to manage its ongoing
investor relations and corporate communications activities with the US
financial community. Skyline is a provider of investor relations and corporate
communications services to public corporations and has offices in Boston,
Massachusetts and New York City.

In addition to the roadshow, BSF will be attending the Future Food Tech Summit
in New York City on 27 and 28 June as part of its strategy to raise its
profile with prospective partners and investors. The event will be attended by
over 800 founders, investors and food brands pioneering alternative proteins.
 More information on the event can be found here: Future Food-Tech
Alternative Proteins Summit (https://www.futurefoodtechprotein.com/)

Che Connon, Managing Director of BSF Enterprise and CEO at 3D Bio Tissues,
commented: "We intend to leverage our US listing to the very best of our
abilities in order to improve our international profile, increase liquidity in
our shares and maximise value for all of our shareholders. This process begins
with our upcoming US investor roadshow, and we look forward to expanding and
developing relationships with the US investment community in the months and
years ahead."

 

Further Information on Skyline Corporate Communications Group, LLC:

Skyline Corporate Communications Group, LLC is an investor relations and
corporate communications firm with offices in Boston, Massachusetts and New
York City. Skyline provides strategic messaging and investor communications
consulting services for public companies worldwide across diverse industries
and market caps. For further information visit Skyline Corporate
Communications Group, LLC's website at: www.skylineccg.com
(https://www.globenewswire.com/Tracker?data=jzXZB5kvMRCijMMHdXUYHcyLHhPvzzupOreiHcdYZRnewitL93zTIvp4KkiTZp96fiSB8TVDJ1BaWa1zLurejaX3T3w9FvlOhZCRTl8hXMw=)
.

-Ends-

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                                                               Via SEC Newgate below
 Che Connon - CEO & Executive Director

 Geoff Baker - Executive Director

 Shard Capital (Broker)
 Damon Heath                                                                      0203 971 7000

 Isabella Pierre

 SEC Newgate (Financial Communications)
 Bob Huxford                                                                      020 3757 6882

 Elisabeth Cowell                                                                 BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
acquiring complementary businesses. It aims to acquire a suite of technologies
that underpins the development of tissue templating for corneas, meat and
leather, and license out the IP to manufacturers, wholesalers and distributors
to help manufacture the products at scale.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPUCPQUPWGRM